Milameline: Nonselective, partial muscarinic receptor agonist for the treatment of Alzheimer's disease?

CNS Drug Reviews

Volumn 5, Issue 2, 1999, Pages 93-104

  Heidrich, A ^a   Rosler M ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b NONE

Author keywords

Alzheimer's disease; CI 979; Milameline; Muscarinic receptor agonist; PD 129409; RU 35926; Tetrahydropyridine aldoxime

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ARECOLINE; MILAMELINE; MUSCARINIC AGENT; OXOTREMORINE; PARTIAL AGONIST; PHOSPHATIDYLINOSITIDE; PILOCARPINE;

ABDOMINAL PAIN; ALZHEIMER DISEASE; AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; HUMAN; HYPERSALIVATION; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; RECEPTOR AFFINITY; REVIEW; SECOND MESSENGER; SUBCUTANEOUS DRUG ADMINISTRATION; SWEATING; VOMITING;

EID: 2442763928     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1999.tb00092.x     Document Type: Review

References (48)

1. Beyreuther K, Masters CL. Nomenclature of amyloid A4 proteins and their precursors in Alzheimer's disease and Down's syndrome. Neurobiol Aging 1990;11:66-68.
2. Bymaster FP, Carter PA, Peters SC et al. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 1998;795:179-190.
3. Callahan MJ. Combined treatment with tacrine and the muscarinic agonist CI-979 (RU-35926) reverses a scopolamine-induced impairment of sustained attention in rhesus monkeys. Soc Neurosci Abstr 1996;22:830.3.
4. Caulfield MP. Muscarinic receptors - characterization, coupling and function. Pharmacol Ther 1993;58:319-379.
5. Cutler NR, Sramek JJ. The target population in Phase I clinical trials of cholinergic compounds in Alzheimer disease: The role of the "Bridging Study." Alzheimer Dis Assoc Disord 1995;9:139-145.
6. Davis R, Raby C, Callahan MJ, et al. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. Prog Brain Res 1993;98:439-445.
7. Dethloff LA, Chang T, Courtney CL. Toxicological comparison of a muscarinic agonist given to rats by gavage or in the diet. Food Chem Toxicol 1996;34:407-422.
8. Durand-Cavagna G, Duprat P. Comments on the pathogenesis of muscarinic agonist-induced corneal opacities in rats. Food Chem Toxicol 1996;34:661.
9. Eikelenboom P, Zhan S-S, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994;15:447-450.
10. Emmerling MR, Moore CJ, Doyle PD, Carroll RT, Davis RE. Cell surface receptor mediated control of amyloid precursor protein secretion: Involvement of pleiotropic signal transduction cascades. In: Hanin I, Yoshida M, Fisher A, eds. Alzheimer's and Parkinson's diseases: Recent Developments. New York: Plenum, 1995:131-139.
11. Emre M, Heckers S, Mash DC, Geula C, Mesulam M-M. Cholinergic innervation of the amygdaloid complex in human brain and its alterations in old age and Alzheimer's disease. J Comp Neurol 1993;336:117-134.
12. Farber SA, Nitsch RM, Schulz JG, Wurtman RJ. Regulated secretion of β-amyloid precursor protein in rat brain. J Neurosci 1995;15:7442-7451.
13. Ferrari-DiLeo G, Mash DC, Flynn DD. Attenuation of muscarinic receptor - G-protein interaction in Alzheimer disease. Mol Chem Neuropathol 1995;24:69-91.
14. Flynn DD, Ferrari-DiLeo G, Levey AI, Mash DC. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: Implications for cholinergic-based therapies. Life Sci 1995;56:869-876.
15. Giacobini E. Pharmacotherapy of Alzheimer disease: New drugs and novel strategies. Prog Brain Res 1993;98:447-454.
16. Graul A, Castaner J. Milameline Hydrochloride. Drugs Future 1996;21:1124-1129.
17. Gurwitz D, Haring R, Heldman E, Pinkas-Kramarski R, Stein R, Fisher A. NGF-dependent neurotrophiclike effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells. Neuroreport 1995;6:485-488.
18. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-1623.
19. Harrison PJ, Barton AJL, Najlerahim A, McDonald B, Pearson RCA. Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstarted by in situ hybridization histochemistry. Brain Res Mol Brain Res 1991;9:15-21.
20. Hartvig P, Torstensen R, Bjurling P, Fasth KJ, Langstrom B, Nordberg A. Regional brain distribution and binding of the muscarinic receptor agonist CI-979 studied by Positron Emission Tomography in the monkey. Dement Geriatr Cogn Disord 1997;8:259-266.
21. Hoover TM. CI-979/RU 35926: A novel muscarinic agonist for the treatment of Alzheimer's disease. In: Giacobini E, Becker R, eds. Alzheimer Disease: Therapeutic Strategies. Boston: Birkhäuser, 1994:239-243.
22. Hoyer S. Neurodegeneration, Alzheimer's disease, and beta-amyloid toxicity. Life Sci 1994;55:1977-1983.
23. Iversen SD. Behavioural evaluation of cholinergic drugs. Life Sci 1997;60:1145-1152.
24. Jaen J, Barrett S, Brann M et al. In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832. Life Sci 1995;6:845-852.
25. Lindenboim L, Pinkas-Kramarski R, Sokolovsky M, Stein R. Activation of muscarinic receptors inhibits apoptosis in PC12M1 cells. J Neurochem 1995;64:2491-2499.
26. Lipinski W, Moore CJ, Bay C, et al. A comparison of the effects of cholinesterase inhibitors and muscarinic agonists on acquisition of a spatial water-maze task by C57BL/10J mice. Soc Neurosci Abstr; 16:374.11.
27. Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am J Pathol 1991;138:235-246.
28. Mattson MP. Secreted forms of beta-amyloid precursor proteins modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J Neurobiol 1994;25:439-450.
29. McConnell HM, Owicki JC, Parce JW, et al. The Cytosensor Microphysiometer: Biological applications of silicon technology. Science 1992;257:1906-1912.
30. M'Harzi M, Palou A-M, Oberlander C, Barzaghi F. Antagonism of scopolamine-induced memory impairments in rats by the muscarinic agonist RU 35926 (CI-979). Pharmacol Biochem Behav 1995:51:119-124.
31. Mitchelson F. Muscarinic receptor differentiation. Pharmacol Ther 1988;37:357-423.
32. Ozawa H, Yamamoto M, Sait T, et al. Regulation of G protein-mediated signal transduction by cytoskeletal elements in Alzheimer's disease brain. Neurobiol Aging (Suppl) 1996;17:S129-S130.
33. Patel S, Freedman SB. The muscarinic-receptor agonist L-658,903 modulates the in vivo accumulation of inositol monophosphates in mouse brain. Eur J Pharmacol 1994;267:329-334.
34. Reece PA, Bockbrader H, Sedman AJ. Safety, pharmacodynamics, and pharmacokinetics of a new muscarinic agonist, CI-979. Clin Exp Pharmacol Physiol (Suppl) 1992;21:58.
35. Sadot E, Gurwitz D, Barg J, Behar L, Fisher A. Activation of M1-muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 1996;66:877-880.
36. Sedman AJ, Bockbader H, Schwarz RD. Preclinical and Phase I clinical characterization of CI-979/RU-35926, a novel muscarinic agonist for the treatment of Alzheimer's disease. Life Sci 1995;56:877-882.
37. Selden N, Geula C, Hersh L, Mesulam M-M. Human striatum: chemoarchitecture of the caudate nucleus, putamen, and ventral striatum in health and Alzheimer's disease. Neuroscience 1994;60:621-636.
38. Soncrant TT, Raffaele KC, Asthana S, Berardi A, Morris PP, Haxby JV. Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. Psychopharmacology 1993;112:421-427.
39. Sramek JJ, Sedman AJ, Reece PA, Hourani J, Bockbader H, Cutler NR. Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 1995;57:503-510.
40. Thai LJ, Grundman M, Klauber MR. Dementia: Characteristics of a referral population and factors associated with progression. Neurology 1988;38:1083-1090.
41. Toja E, Bonetti C, Butti A. et al. 1-Alkyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyl-oximes: A new class of potent orally active muscarinic agonists related to arecoline. Eur J Med Chem 1991;26:853-868.
42. Trojanowski JQ, Lee VM-Y. Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: Focusing on phosphatases. FASEB J 1995;9:1570-1576.
43. Van Leeuwen FW, Burbach JPH, Hol EM. Mutations in RNA: a first example of molecular misreading in Alzheimer's disease. Trends Neurosci 1998;21:331-335.
44. Wang S-Z, Zhu S-Z, Mash DC, El-Fakahany EE. Comparison of the concentration of messenger RNA coding for muscarinic receptor subtypes in control and Alzheimer brains. Brain Res Mol Brain Res 1992;16:64-70.
45. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
46. Windsor BL, Radulovic LL, Bockbrader HN, Chang T. Measurement of CI-979 (a candidate drug for the treatment of age-related disorders of cognition) in human plasma by capillary gas chromatography with nitrogen-selective detection. J Chromatogr 1993;619:315-318.
47. Windsor BL, Radulovic LL, Bockbrader HN, et al. Application of a validated GC/NPD method for quantitation of CI-979 in a clinical interaction study with Maalox TC®. Pharm Res (Suppl) 1993;1:S415.
48. Wimer RE, Wimer CC, Chernow CR, Belvanz BA. The genetic organization of neuron number in the pyramidal cell layer of hippocampal region superior in house mice. Brain Res 1980;196:59-77.